Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality

Transplantation

Volumn 96, Issue 9, 2013, Pages 807-813

  Costa, Nadiesda A ^a   Kshirsagar, Abhijit V ^a   Wang, Lily ^b   Detwiler, Randal K ^a   Brookhart, M Alan ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

Author keywords

Allograft failure; Allograft loss; End stage kidney disease; ESA; Mortality

Indexed keywords

ANTIANEMIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HEMATOCRIT; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORBIDITY; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT RESPONSE; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMATINICS; HEMATOCRIT; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MEDICARE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84888297209     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182a0f668     Document Type: Article

References (66)

1. USRDS. 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the united states. Bethesda, MD: United States Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive Diseases; 2010
2. United Network for Organ Sharing. United States Department of Health and Human Services, Organ Procurement and Transplantation Network data as of March 16, 2011, available at http://optn.transplant. hrsa.gov
3. Woo YM, Jardine AG, Clark AF, et al. Early graft function and patient survival following cadaveric renal transplantation. Kidney Int 1999; 55: 692
4. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. Rockville, MD: U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2009
5. Port FK, Dykstra DM, Merion RM, et al. Trends and results for organ donation and transplantation in the united states, 2004. Am J Transplant 2005; 5: 843
6. Sellers MT, Velidedeoglu E, Bloom RD, et al. Expanded-criteria donor kidneys: A single-center clinical and short-term financial analysisVcause for concern in retransplantation. Transplantation 2004; 78: 1670
7. Woo YM, Gill JS, Johnson N, et al. The advanced age deceased kidney donor: Current outcomes and future opportunities. Kidney Int 2005; 67: 2407
8. Schold JD, Kaplan B, Baliga RS, et al. The broad spectrum of quality in deceased donor kidneys. Am J Transplant 2005; 5: 757
9. Wu C, Evans I, Joseph R, et al. Comorbid conditions in kidney transplantation: Association with graft and patient survival. J Am Soc Nephrol 2005; 16: 3437
10. Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004; 15: S25
11. Abbott KC, Glanton CW, Trespalacios FC, et al. Body mass index, dialysis modality, and survival: Analysis of the united states Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004; 65: 597
12. Hill GS, Nochy D, Bruneval P, et al. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22: 975
13. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 2004; 4: 438
14. Knoll G. Trends in kidney transplantation over the past decade. Drugs 2008; 68: 3
15. Kinney R. Centers for Medicare and Medicaid Services; 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 2006; 48: S1
16. Sautner T, Gnant M, Banhegyi C, et al. Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. Transpl Int 1992; 5: S116
17. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085
18. Pfeffer MA, Burdmann EA, Chen CY, et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Am J Kidney Dis 2009; 54: 59
19. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584
20. Brookhart MA, Schneeweiss S, Avorn J, et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010; 303: 857
21. Cotter DJ, Thamer M, Zhang Y. Relative mortality and epoetin alpha dose in hemodialysis patients. Am J Kidney Dis 2008; 51: 865; author reply 865
22. Szczech LA. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791
23. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146
24. Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077
25. Abedini S, Holme I, Marz W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4: 1246
26. Campise M, Mikhail A, Quaschning T, et al. Impact of pre-transplant anaemia correction and erythropoietin resistance on long-term graft survival. Nephrol Dial Transplant 2005; 20: Viii8
27. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387
28. Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1: 92
29. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet 2010; 375: 132
30. Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: A systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 483
31. Kalantar-Zadeh K. Inflammatory marker mania in chronic kidney disease: Pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol 2007; 2: 872
32. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004; 291: 451
33. Kaysen GA. The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549
34. Zimmermann J. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648
35. Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469
36. Van Ree RM, Gross S, Zelle DM, et al. Influence of C-reactive protein and urinary protein excretion on prediction of graft failure and mortality by serum albumin in renal transplant recipients. Transplantation 2010; 89: 1247
37. Rahmati MA, Craig RG, Homel P, et al. Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am J Kidney Dis 2002; 40: 983
38. Chen LP, Chiang CK, Chan CP, et al. Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients? Am J Kidney Dis 2006; 47: 815
39. Kshirsagar AV, Craig RG, Beck JD, et al. Severe periodontitis is associated with low serum albumin among patients on maintenance hemodialysis therapy. Clin J Am Soc Nephrol 2007; 2: 239
40. Ayus JC, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998; 9: 1314
41. Roberts TL, Obrador GT, St Peter WL, et al. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 2004; 66: 2429
42. Cappelli G, Tetta C, Canaud B. Is biofilm a cause of silent chronic inflammation in haemodialysis patients? A fascinating working hypothesis. Nephrol Dial Transplant 2005; 20: 266
43. Schiffl H, Lang SM, Stratakis D, et al. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 2001; 16: 1863
44. Arizono K, Nomura K,Motoyama T, et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif 2004; 22: 26
45. Rahmati MA, Homel P, Hoenich NA, et al. The role of improved water quality on inflammatory markers in patients undergoing regular dialysis. Int J Artif Organs 2004; 27: 723
46. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524
47. Parkkinen J, von Bonsdorff L, Peltonen S, et al. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. ironsaccharate administration. Nephrol Dial Transplant 2000; 15: 1827
48. Brewster UC, Perazella MA. Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 2004; 17: 57
49. Bullen JJ, Rogers HJ, Spalding PB, et al. Iron and infection: The heart of the matter. FEMS Immunol Med Microbiol 2005; 43: 325
50. Collins AJ EJ, Ma JZ, Xia H. Iron dosing patterns and mortality. J Am Soc Nephrol 1998; 9: 205A. 51
51. Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984; 219: 1
52. Sevanian A, Hochstein P. Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr 1985; 5: 365
53. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20: 707
54. Brewster UC. Intravenous iron therapy in end-stage renal disease. Semin Dial 2006; 19: 285
55. Barany P, Divino Filho J, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565
56. Gunnell J. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63
57. de Francisco AL, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: From haemoglobin variability to hyporesponsiveness. NDT Plus 2009; 2: I18
58. Malyszko J, Malyszko JS, Borawski J, et al. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995; 77: 133
59. Fuste B, Serradell M, Escolar G, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 678
60. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52: 727
61. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983
62. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009; 4: 470
63. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071
64. Kamar N, Reboux AH, Cointault O, et al. Impact of very early high doses of recombinant erythropoietin on anemia and allograft function in de novo kidney-transplant patients. Transpl Int 2010; 23: 277
65. Heinze G, Kainz A, Horl WH, et al. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: Cohort study. BMJ 2009; 339: B4018
66. Fernandez Fresnedo G, de Francisco AL, Ruiz JC, et al. Hemoglobin level variability in renal transplant patients treated with erythropoiesis stimulating agents. Transplant Proc 2008; 40: 2919